Experience

PureTech Health

• United States
• Biotechnology
• 1 - 100 Employee

• President and Chief Business, Legal & Operating Officer

  • Mar 2017 - Present

  Boston, Massachusetts PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive… Show more PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 25 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization, as of the date of PureTech's most recently filed Half Year Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on the Company's unique insights into the biology of the brain, immune and gut, or BIG, systems and the interface between those systems, referred to as the BIG Axis. For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh. Show less



Synlogic

• United States
• Biotechnology Research
• 1 - 100 Employee

• President

  • Sep 2015 - Feb 2017

  Cambridge, Massachusetts Synlogic is a privately-held biopharmaceutical company based in Cambridge, Massachusetts, pioneering the development of a novel class of oral therapeutics based on its proprietary synthetic biology and microbiome, called “synthetic biotics” technology platform. The synthetic biotic approach involves precision programming of naturally occurring microorganisms with unique and proprietary genetic circuits to generate microorganisms (bacteria or virus) with exquisite genetic control to power the… Show more Synlogic is a privately-held biopharmaceutical company based in Cambridge, Massachusetts, pioneering the development of a novel class of oral therapeutics based on its proprietary synthetic biology and microbiome, called “synthetic biotics” technology platform. The synthetic biotic approach involves precision programming of naturally occurring microorganisms with unique and proprietary genetic circuits to generate microorganisms (bacteria or virus) with exquisite genetic control to power the microbiome. These novel orally administered “designer” microorganism-based therapies have the potential to safely and effectively halt or reverse the course of disease progression and revolutionize the treatment paradigm for a broad range of serious debilitating diseases including rare diseases. Synlogic’s synthetic biotics technology platform also has applications in the development of nutritional medical products. Synlogic’s two lead therapeutic programs are being developed for the potential treatment of rare inborn errors of metabolism (IEM) of Urea Cycle Disorder (UCD) and Phenylketonuria (PKU). In addition to the company’s proprietary pipeline focused on rare diseases, the company is leveraging its broad synthetic biotics platform in drug development programs beyond rare diseases through partnerships with other pharmaceutical and biotechnology companies. As a part of this strategy, Synlogic has entered into an R&D collaboration with AbbVie for the treatment of certain forms of inflammatory bowel disease (IBD) such as Crohn’s disease and ulcerative colitis. Founded in 2014, Synlogic is backed by leading life sciences investors, including Atlas Venture, New Enterprise Associates (NEA) and the Bill & Melinda Gates Foundation. For more information, please visit: http://www.synlogictx.com/. Show less



Auspex Pharmaceuticals, a Division of Teva Pharmaceutical Industries, Ltd.

• Chief Operating Officer

  • Oct 2013 - Jul 2015

  Greater San Diego Area Auspex Pharmaceuticals was a NASDAQ-listed, late-clinical stage biopharmaceutical company dedicated to developing innovative medicines for hyperkinetic movement disorders and other rare diseases. Auspex employs its proprietary technology to create patent-protected, new chemical entities from known, clinically proven therapies. The company's lead product, SD-809 (deutetrabenazine), is in final stages of development for the treatment of chorea associated with Huntington's disease, a… Show more Auspex Pharmaceuticals was a NASDAQ-listed, late-clinical stage biopharmaceutical company dedicated to developing innovative medicines for hyperkinetic movement disorders and other rare diseases. Auspex employs its proprietary technology to create patent-protected, new chemical entities from known, clinically proven therapies. The company's lead product, SD-809 (deutetrabenazine), is in final stages of development for the treatment of chorea associated with Huntington's disease, a neurodegenerative movement disorder that impacts cognition, behavior and movements. In addition, Auspex is investing in the broad potential of SD-809 for the treatment of other movement disorders, including tardive dyskinesia and tics associated with Tourette’s syndrome. The company's pipeline also includes SD-560, being developed for fibrotic conditions, and SD-1077, which is being developed for Parkinson's disease. Auspex was acquired by Teva Pharmaceutical Industries Ltd., on May 5, 2015 for $3.5 Billion. For further information, please visit the company's website www.tevapharma.com Show less



Addex Therapeutics

• President & CEO

  • 2011 - Jul 2013

  San Francisco Bay Area Addex Therapeutics (SIX:ADXN), is a leading biopharmaceutical company pioneering allosteric modulation-based drug discovery and development. Addex discovers and develops an emerging class of small molecule drugs, called allosteric modulators, which have the potential to be more specific and confer significant therapeutic advantages over conventional “orthosteric” small molecule or biological drugs.



Nektar Therapeutics

• Biotechnology
• 300 - 400 Employee

• SVP & Chief Operating Officer

  • May 2008 - Jan 2011

• Chairman

  • May 2008 - Jan 2011



Merck

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• VP, Sirna & Executive Director, Worldwide Licensing

  • Jan 2007 - May 2008

• Ex Dir, Licensing

  • 2007 - 2008



Sirna Therapeutics

• Biotechnology Research

• VP, Legal & Chief Patent Counsel

  • Jun 1993 - Dec 2006

  Sirna acquired by Merck & Co for $1.1 Billion in 2006! Sirna was a relaunch of Ribozyme Pharmaceuticals in 2003.



Sirna Therapeutics (A wholly owned subsidiary of Merck)

• Head of Legal Affairs

  • 2003 - 2006



Ribozyme Pharmaceuticals

• Biotechnology

• Chief Patent Counsel

  • 1993 - 2003

• Chief Patent Counsel

  • 1993 - 2003



University of Vermont

• United States
• Higher Education
• 700 & Above Employee

• Post Doctoral Fellow

  • 1990 - 1993